- In February 2023, Philips introduced a multiparametric MRI and MRI/ultrasound fusion approach for prostate cancer diagnosis. This technique improves diagnostic accuracy by using MRI to identify suspicious lesions in the prostate, helping urologists to better target biopsies. The fusion of MRI and ultrasound images allows for real-time, precise targeting of high-risk cancerous areas, offering an alternative to traditional biopsies. The technology enhances the ability to detect clinically significant prostate cancer early, providing a more confident diagnosis and faster initiation of treatment. This advancement aims to improve patient outcomes, particularly for those with prior negative biopsies
Frequently Asked Questions
Companies such as Eigen Technologies (U.S.), Koninklijke Philips N.V. (Netherlands), Hitachi (Japan), MedCom Solutions, Inc (Germany), Esaote SPA (Italy), KOELIS (France), GE HealthCare (U.S.), are the major companies in the fusion biopsy market.
In February 2023, Philips introduced a multiparametric MRI and MRI/ultrasound fusion technique for prostate cancer diagnosis, improving accuracy by precisely targeting suspicious lesions. This method enhances early detection, enabling more confident diagnoses and quicker treatment initiation, especially for patients with previous negative biopsies.
The countries covered in the fusion biopsy market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
